Deoxyhypusine hydroxylase (DOHH) is a novel metalloenzyme that catalyzes the final step of the post-translational synthesis of hypusine (N ⑀ -(4-amino-2-hydroxybutyl)lysine) in the eukaryotic translation initiation factor 5A (eIF5A). Hypusine synthesis is unique in that it occurs in only one protein, denoting the strict specificity of the modification enzymes toward the substrate protein. The specificity of the interaction between eIF5A and DOHH was investigated using human eIF5A (eIF5A-1 isoform) and human recombinant DOHH. DOHH displayed a strong preference for binding the deoxyhypusine-containing form of eIF5A, over the eIF5A precursor or the hypusine-containing eIF5A, indicating a role for the deoxyhypusine residue in binding. In addition to the deoxyhypusine residue, a large portion of the eIF5A polypeptide (>20 -90 amino acids) is required for effective modification by DOHH. We have identified the amino acid residues of DOHH that are critical for substrate binding by alanine substitution of 36 conserved amino acid residues. Of these, alanine substitution at Glu 57 is an unusual amino acid that occurs in all eukaryotes. It is formed posttranslationally in eukaryotic translation initiation factor 5A (eIF5A) 4 through the action of two enzymes (for a recent review, see Ref. 1). The first enzyme, deoxyhypusine synthase (DHS), catalyzes the NAD-dependent cleavage of spermidine and transfer of its 4-aminobutyl moiety to the ⑀-amino group of a specific lysine residue to form the deoxyhypusine (N ⑀ -(4-aminobutyl)lysine) residue (2, 3). The second enzyme, deoxyhypusine hydroxylase (DOHH), hydroxylates this intermediate to form the hypusine residue and mature eIF5A (4, 5).eIF5A and its modification enzymes, DHS and DOHH, are essential for mammalian cell proliferation (1, 6 -11). Various metal chelating inhibitors of DOHH, including mimosine and ciclopirox olamine, inhibit cell proliferation by causing cell cycle arrest at the G 1 /S boundary (12). Ciclolopirox olamine, in particular, exerted strong inhibition of human umbilical vein endothelial cell (HUVEC) proliferation and angiogenesis in model assays, suggesting the potential utility of DOHH inhibitors as antitumor agents (13). Although DOHH has been proposed as a potential target of antitumor therapy (13) and antihuman immunodeficiency virus type 1 therapy (14), no specific inhibitors of DOHH are currently available.The unique feature of hypusine formation is the strict substrate specificity of this protein modification. Hypusine synthesis occurs exclusively in one cellular protein, eIF5A precursor, at one specific lysine residue (Lys 50 for the human protein) and thereby represents one of the most specific protein modifications known to date. eIF5A and its modifying enzymes, DHS and DOHH, are highly conserved in all eukaryotes (1,8). The amino acid sequence conservation surrounding the hypusine site of eIF5A is especially high in eukaryotes, suggesting that the hypusine residue has an important basic function that has been preserved through evolution. Furthe...